Physician profile
Bassel Nazha
NPI 1215349964
$6,709.98
in general payments reported to CMS, 2019-2025
25 companies · $4,662 in 2025
The $4,662 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.10 · 2021: $1,470 · 2023: $269 · 2024: $217 · 2025: $4,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,998 · Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,997.50 |
| Food and Beverage | $1,151.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,904.96 | 2021-2024 | Cabometyx |
| Pfizer INC. | $1,545.25 | 2025 | |
| Janssen Biotech, INC. | $1,414.46 | 2025 | Erleada, Darzalex |
| Janssen Scientific Affairs, LLC | $1,110.00 | 2025 | Erleada |
| Genentech USA, INC. | $91.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $84.04 | 2025 | |
| Merck Sharp & Dohme LLC | $56.02 | 2025 | Keytruda, Reblozyl, Welireg |
| Daiichi Sankyo INC. | $54.65 | 2025 | Enhertu, Datroway |
| Verity Pharmaceuticals INC. | $51.84 | 2024 | Trelstar |
| Glaxosmithkline, LLC. | $51.34 | 2025 | Ojjaara |
| Astrazeneca Pharmaceuticals LP | $49.53 | 2025 | |
| Sumitomo Pharma America, INC. | $42.84 | 2025 | Orgovyx |
| Abbvie INC. | $35.97 | 2025 | |
| Nuvation Bio INC. | $30.14 | 2025 | Ibtrozi |
| Karyopharm Therapeutics INC. | $26.61 | 2025 | Xpovio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $24.86 | 2025 | Zynyz, Monjuvi |
| Shield Therapeutics INC | $24.77 | 2025 | |
| Dendreon Pharmaceuticals LLC | $24.24 | 2025 | Provenge |
| Astellas Pharma US INC | $23.11 | 2025 | Vyloy |
| Aveo Pharmaceuticals, INC. | $22.04 | 2025 | |
| Alexion Pharmaceuticals, INC. | $20.33 | 2025 | Ultomiris |
| Beone Medicines USA, INC. | $19.98 | 2025 | Brukinsa |
| Array Biopharma INC | $1.90 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassel Nazha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.